T-DXd

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases

Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma

Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast Cancer

T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer

Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

Efficacy of T-Dxd in the Treatment of HER2-positive BCBM After Prior Pyrotinib